1. Home
  2. GNPX vs NLSP Comparison

GNPX vs NLSP Comparison

Compare GNPX & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GNPX
  • NLSP
  • Stock Information
  • Founded
  • GNPX 2009
  • NLSP 2015
  • Country
  • GNPX United States
  • NLSP Switzerland
  • Employees
  • GNPX N/A
  • NLSP N/A
  • Industry
  • GNPX Biotechnology: Pharmaceutical Preparations
  • NLSP Biotechnology: Pharmaceutical Preparations
  • Sector
  • GNPX Health Care
  • NLSP Health Care
  • Exchange
  • GNPX Nasdaq
  • NLSP Nasdaq
  • Market Cap
  • GNPX 6.1M
  • NLSP 6.2M
  • IPO Year
  • GNPX 2018
  • NLSP 2021
  • Fundamental
  • Price
  • GNPX $0.75
  • NLSP $1.89
  • Analyst Decision
  • GNPX Strong Buy
  • NLSP
  • Analyst Count
  • GNPX 1
  • NLSP 0
  • Target Price
  • GNPX $10.00
  • NLSP N/A
  • AVG Volume (30 Days)
  • GNPX 367.1K
  • NLSP 2.2M
  • Earning Date
  • GNPX 11-13-2024
  • NLSP 10-18-2024
  • Dividend Yield
  • GNPX N/A
  • NLSP N/A
  • EPS Growth
  • GNPX N/A
  • NLSP N/A
  • EPS
  • GNPX N/A
  • NLSP N/A
  • Revenue
  • GNPX N/A
  • NLSP N/A
  • Revenue This Year
  • GNPX N/A
  • NLSP N/A
  • Revenue Next Year
  • GNPX N/A
  • NLSP N/A
  • P/E Ratio
  • GNPX N/A
  • NLSP N/A
  • Revenue Growth
  • GNPX N/A
  • NLSP N/A
  • 52 Week Low
  • GNPX $0.28
  • NLSP $1.73
  • 52 Week High
  • GNPX $13.00
  • NLSP $20.80
  • Technical
  • Relative Strength Index (RSI)
  • GNPX 40.74
  • NLSP 41.06
  • Support Level
  • GNPX $0.66
  • NLSP $1.87
  • Resistance Level
  • GNPX $0.74
  • NLSP $2.08
  • Average True Range (ATR)
  • GNPX 0.06
  • NLSP 0.23
  • MACD
  • GNPX 0.00
  • NLSP 0.02
  • Stochastic Oscillator
  • GNPX 35.04
  • NLSP 5.81

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.

About NLSP NLS Pharmaceutics Ltd.

NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.

Share on Social Networks: